|
Overall (%)
|
43 (33)
|
11 (11)
|
<0.001
|
|
Unauthorized indication
|
0
|
0
|
NA
|
|
Violation of contraindications
|
|
eGFR < 30 mL/min/1.73 m2
|
0 [0]
|
0 [0]
|
NA
|
|
CLCr < 30 mL/min
|
2 [50]
|
0 [80]
|
0.15
|
|
Concomitant use with oral itraconazole
|
0
|
0
|
NA
|
|
Active bleeding or hemorrhagic diathesis
|
0
|
0
|
NA
|
|
History of complications associated with high-risk of bleeding (cerebral hemorrhage) in the latest 6 months
|
0
|
0
|
NA
|
|
Concomitant dwelling of spinal or epidural catheters
|
0
|
0
|
NA
|
|
History of serious hypersensitivity reaction to Prazaxa®
|
0
|
0
|
NA
|
|
Inappropriate dose selection in reference to age
|
|
Overdose for patients ≥ 70 years (%)
|
14/77 (18)
|
2/56 (4)
|
<0.05
|
|
Underdose for patients ≥ 70 years (%)
|
2/77 (3)
|
1/56 (2)
|
NS
|
|
Overdose for patients < 70 years (%)
|
0/54 (0)
|
0/41 (0)
|
NA
|
|
Underdose for patients < 70 years (%)
|
3/54 (6)
|
0/41 (0)
|
NS
|
|
Non-compliance with the recommendations for dose reduction
|
|
eGFR from 30 to 50 mL/min/1.73 m2 (%)
|
2/22 (9)
|
1/10 (10)
|
NS
|
|
CLcr from 30 to 50 mL/min
|
0/11 (0)
|
1/15 (7)
|
NS
|
|
Past medical history of gastrointestinal bleeding (%)
|
1/5 (20)
|
3/5 (60)
|
NS
|
|
Concomitant use of verapamil (%)
|
7/10 (70)
|
3/7 (43)
|
NS
|
|
No assessment of renal function (%)
|
1/131 (1)
|
0/97 (0)
|
NS
|
|
PT-INR < 2.0 when dabigatran was started after discontinuation of warfarin
|
14/54 (26)
|
1/21 (5)
|
0.053
|
